Poly(I:C) enhances the efficacy of phagocytosis checkpoint blockade immunotherapy by inducing IL-6 production

J Leukoc Biol. 2021 Dec;110(6):1197-1208. doi: 10.1002/JLB.5MA0421-013R. Epub 2021 May 14.

Abstract

Macrophage phagocytosis plays essential roles in antitumor immunity. CD47/SIRPα phagocytosis checkpoint blockade has demonstrated therapeutic potential in several hematopoietic cancers, but recent clinical studies reported very limited efficacy against solid malignancies. Here, we show that polyinosinic-polycytidylic acid (Poly(I:C)), a synthetic analog of double-stranded RNA, enhances the antitumor activity of CD47 blockade in colorectal cancer in vitro and in vivo. Poly(I:C) activation leads to a potent immune response characterized by the production of proinflammatory cytokines, especially IL-6. Stimulation with IL-6 promotes the PI3K signaling and cytoskeletal reorganization required for macrophage phagocytosis mediated by CD47 blockade. Our findings demonstrate the potential of Poly(I:C) to synergize the efficacy of CD47 blockade therapy and a novel role for IL-6 in macrophage phagocytosis, which provide new strategy for combinational cancer immunotherapy.

Keywords: IL-6; Poly(I:C); immunotherapy efficacy; phagocytosis checkpoint blockade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD47 Antigen / antagonists & inhibitors
  • Colorectal Neoplasms / immunology*
  • Immune Checkpoint Inhibitors / immunology
  • Immunotherapy / methods*
  • Interferon Inducers / pharmacology
  • Interleukin-6 / biosynthesis*
  • Macrophages / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Phagocytosis / drug effects
  • Phagocytosis / immunology
  • Poly I-C / pharmacology*

Substances

  • CD47 Antigen
  • Immune Checkpoint Inhibitors
  • Interferon Inducers
  • Interleukin-6
  • Poly I-C